AP1747A - Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. - Google Patents
Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal.Info
- Publication number
- AP1747A AP1747A AP2005003272A AP2005003272A AP1747A AP 1747 A AP1747 A AP 1747A AP 2005003272 A AP2005003272 A AP 2005003272A AP 2005003272 A AP2005003272 A AP 2005003272A AP 1747 A AP1747 A AP 1747A
- Authority
- AP
- ARIPO
- Prior art keywords
- äimino
- ylü
- methylüpiperazine
- methylsulfanylphenyl
- indol
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20913600P | 2000-06-02 | 2000-06-02 | |
US21217200P | 2000-06-16 | 2000-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2005003272A0 AP2005003272A0 (en) | 2005-03-31 |
AP1747A true AP1747A (en) | 2007-05-31 |
Family
ID=26903852
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2005003272A AP1747A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. |
APAP/P/2001/002180A AP1831A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2001/002180A AP1831A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia. |
Country Status (44)
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004054487A2 (en) | 2002-12-13 | 2004-07-01 | Regents Of The University Of Minnesota | Scleral depressor |
US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
JP2012174228A (ja) * | 2011-02-24 | 2012-09-10 | Kyocera Corp | プログラム保護装置および通信装置 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0985414A2 (en) * | 1998-05-26 | 2000-03-15 | Pfizer Products Inc. | Method of treating glaucoma and ischemic retinopathy |
WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
IL126590A (en) * | 1996-05-07 | 2001-11-25 | Pfizer | Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it |
-
2001
- 2001-05-28 EP EP06116051A patent/EP1698338B1/en not_active Expired - Lifetime
- 2001-05-28 EP EP01932011A patent/EP1286672B1/en not_active Expired - Lifetime
- 2001-05-28 NZ NZ551012A patent/NZ551012A/en unknown
- 2001-05-28 AU AU2001258690A patent/AU2001258690A1/en not_active Abandoned
- 2001-05-28 YU YU90702A patent/YU90702A/sh unknown
- 2001-05-28 PL PL01365576A patent/PL365576A1/xx unknown
- 2001-05-28 SI SI200130681T patent/SI1468686T1/sl unknown
- 2001-05-28 BR BR0111271-6A patent/BR0111271A/pt not_active Application Discontinuation
- 2001-05-28 AT AT06116051T patent/ATE391507T1/de not_active IP Right Cessation
- 2001-05-28 GE GE4972A patent/GEP20053512B/en unknown
- 2001-05-28 CA CA002410618A patent/CA2410618A1/en not_active Abandoned
- 2001-05-28 EE EEP200200670A patent/EE200200670A/xx unknown
- 2001-05-28 JP JP2001587771A patent/JP2003534381A/ja not_active Withdrawn
- 2001-05-28 SK SK1662-2002A patent/SK16622002A3/sk not_active Application Discontinuation
- 2001-05-28 ES ES04013380T patent/ES2277170T3/es not_active Expired - Lifetime
- 2001-05-28 OA OA1200200349A patent/OA12267A/en unknown
- 2001-05-28 CN CN01810620A patent/CN1431901A/zh active Pending
- 2001-05-28 IL IL15278201A patent/IL152782A0/xx active IP Right Grant
- 2001-05-28 DE DE60133596T patent/DE60133596D1/de not_active Expired - Lifetime
- 2001-05-28 PT PT04013380T patent/PT1468686E/pt unknown
- 2001-05-28 MX MXPA02011862A patent/MXPA02011862A/es active IP Right Grant
- 2001-05-28 EP EP04013380A patent/EP1468686B1/en not_active Expired - Lifetime
- 2001-05-28 DK DK04013380T patent/DK1468686T3/da active
- 2001-05-28 CZ CZ20023860A patent/CZ20023860A3/cs unknown
- 2001-05-28 HU HU0301747A patent/HUP0301747A2/hu unknown
- 2001-05-28 WO PCT/IB2001/000933 patent/WO2001091756A2/en active IP Right Grant
- 2001-05-28 AT AT04013380T patent/ATE345818T1/de not_active IP Right Cessation
- 2001-05-28 KR KR1020027016364A patent/KR20030007824A/ko not_active Application Discontinuation
- 2001-05-28 AT AT01932011T patent/ATE343387T1/de not_active IP Right Cessation
- 2001-05-28 UA UA2002119557A patent/UA79425C2/uk unknown
- 2001-05-28 DE DE60124791T patent/DE60124791T2/de not_active Expired - Fee Related
- 2001-05-28 PT PT06116051T patent/PT1698338E/pt unknown
- 2001-05-28 DE DE60124093T patent/DE60124093D1/de not_active Expired - Lifetime
- 2001-05-28 EA EA200201168A patent/EA007068B1/ru not_active IP Right Cessation
- 2001-05-31 PE PE2001000504A patent/PE20011329A1/es not_active Application Discontinuation
- 2001-05-31 UY UY26742A patent/UY26742A1/es not_active Application Discontinuation
- 2001-05-31 AP AP2005003272A patent/AP1747A/xx active
- 2001-05-31 DO DO2001000181A patent/DOP2001000181A/es unknown
- 2001-05-31 AP APAP/P/2001/002180A patent/AP1831A/en active
- 2001-05-31 HN HN2001000119A patent/HN2001000119A/es unknown
- 2001-06-01 PA PA20018518301A patent/PA8518301A1/es unknown
- 2001-06-01 AR ARP010102641A patent/AR028937A1/es unknown
- 2001-06-01 SV SV2001000473A patent/SV2002000473A/es not_active Application Discontinuation
- 2001-06-04 US US09/873,973 patent/US20060287336A1/en not_active Abandoned
-
2002
- 2002-11-11 IL IL152782A patent/IL152782A/en not_active IP Right Cessation
- 2002-11-12 BG BG107267A patent/BG107267A/bg unknown
- 2002-11-14 IS IS6619A patent/IS6619A/is unknown
- 2002-11-28 ZA ZA200209665A patent/ZA200209665B/en unknown
- 2002-11-29 EC EC2002004369A patent/ECSP024369A/es unknown
- 2002-11-29 MA MA26927A patent/MA26908A1/fr unknown
- 2002-11-29 NO NO20025760A patent/NO325077B1/no unknown
- 2002-12-02 HR HR20020953A patent/HRP20020953A2/hr not_active Application Discontinuation
-
2007
- 2007-02-08 CY CY20071100161T patent/CY1105992T1/el unknown
- 2007-11-14 JP JP2007296039A patent/JP2008056700A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0985414A2 (en) * | 1998-05-26 | 2000-03-15 | Pfizer Products Inc. | Method of treating glaucoma and ischemic retinopathy |
WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
Non-Patent Citations (1)
Title |
---|
PRAKASH C ET AL: DRUG METABOLISM AND DISPOSITION, vol. 25, no. 7, July 1997, pages 863-872 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1053118A1 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof. | |
HK1076387A1 (en) | Use in the preparation of a combination medicament for the treatment or prevention of an immunoinflammatory disorder | |
MXPA03005731A (es) | Articulo absorbente que tiene tratamientos medicinales liberables. | |
HK1061679A1 (en) | Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use. | |
PL362690A1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
PT1827396T (pt) | Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular | |
AU2001292297A1 (en) | Mouthpiece for orthodontic treatment and device for orthodontic treatment using the mouthpiece | |
PL388076A1 (pl) | Doustna postać dawki o przedłużonym uwalnianiu oksykodonu i jej zastosowanie | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
ZA200203156B (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders. | |
HRP20010655B1 (en) | Pyridopyranoazepine derivatives, preparation and therapeutic use | |
HUP0301333A2 (hu) | Gyógyszer szuperdezintegráns, eljárás az előállítására és alkalmazása | |
GB2368525B (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
AU2001264044A1 (en) | 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof | |
ZA200001746B (en) | 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use. | |
MXPA02012249A (es) | Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia. | |
ZA200004406B (en) | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal. | |
ZA200200222B (en) | Titanium derived compounds, preparation and use thereof. | |
ZA200400313B (en) | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine. | |
AP1747A (en) | Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. | |
ZA200205464B (en) | Device for preventing or relieving pain in the lower back. | |
HUP0201810A2 (en) | Sootepenseone and its derivatives, their preparation and use as medicament | |
MXPA03003032A (es) | Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. | |
AU2002215187A1 (en) | S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease |